• 08 FEB 2017
    • 0

    PharmaCyte Biotech Releases Shareholder Call and Complete Q&A Playback Information

    LAGUNA HILLS, Calif., Feb. 08, 2017 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that an audio recording of the company’s shareholder call, which was held on February 7, 2017, by the Chief Executive

    Read more →
    • 02 FEB 2017
    • 0

    PharmaCyte Biotech Provides Update for February 7th Shareholder Call

    LAGUNA HILLS, Calif., Feb. 02, 2017 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that during its upcoming shareholder call PharmaCyte’s Chief Executive Officer, Kenneth L. Waggoner, will update shareholders on PharmaCyte’s clinical trial

    Read more →
    • 30 JAN 2017
    • 0

    PharmaCyte Biotech Retains Facet Life Sciences to Guide Pancreatic Cancer Therapy Development Lifecycle with FDA

    LAGUNA HILLS, Calif., Jan. 30, 2017 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, officially announced today that PharmaCyte has retained Facet Life Sciences, Inc. (Facet) to guide PharmaCyte through its pancreatic cancer therapy development

    Read more →
    • 18 JAN 2017
    • 0

    PharmaCyte Biotech to Hold Shareholder Call

    LAGUNA HILLS, Calif., Jan. 18, 2017 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that Chief Executive Officer Kenneth L. Waggoner will conduct a shareholder conference call at 4:30 p.m. EST on Tuesday,

    Read more →
    • 10 JAN 2017
    • 0

    PharmaCyte Biotech Discusses Upcoming Clinical Trial with Principal Investigator Dr. Manuel Hidalgo

    Read more →
    • 04 JAN 2017
    • 0

    PharmaCyte Biotech Announces Pre-IND Meeting Date with FDA

    LAGUNA HILLS, Calif., Jan. 04, 2017 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that it will be meeting with the Center for Biologics Evaluation and Research (CBER) of the U.S. Food and

    Read more →
    • 27 DEC 2016
    • 0

    PharmaCyte Biotech’s Cannabinoid Therapy May Offer Potential for Childhood Brain Cancers

    LAGUNA HILLS, Calif., Dec. 27, 2016 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that recent research performed at the Ann and Robert H. Lurie Children’s Hospital of Chicago and Northwestern University’s Feinberg

    Read more →
    • 15 DEC 2016
    • 0

    PharmaCyte Biotech Submits Pre-IND Meeting Package to FDA

    LAGUNA HILLS, Calif., Dec. 15, 2016 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that it has submitted its pre-Investigational New Drug (pre-IND) meeting package to the U.S. Food and Drug Administration (FDA) for PharmaCyte’s

    Read more →
    • 07 DEC 2016
    • 0

    PharmaCyte Biotech Discusses Upcoming Clinical Trial in Pancreatic Cancer with First Principal Investigator

    LAGUNA HILLS, Calif., Dec. 07, 2016 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, released today the first article in a series of Q&A articles that will be conducted with some of the key team

    Read more →
    • 29 NOV 2016
    • 0

    PharmaCyte Biotech Granted FDA Pre-IND Meeting for Pancreatic Cancer Therapy

    LAGUNA HILLS, Calif., Nov. 29, 2016 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that a Pre-Investigational New Drug (Pre-IND) meeting with the Center for Biologics Evaluation and Research (CBER) of the U.S.

    Read more →